167 related articles for article (PubMed ID: 32106310)
21.
Onaindia A; de Villambrosía SG; Prieto-Torres L; Rodríguez-Pinilla SM; Montes-Moreno S; González-Vela C; Piris MA
Haematologica; 2019 Apr; 104(4):e158-e162. PubMed ID: 30361415
[No Abstract] [Full Text] [Related]
22. Expression of the chemokine receptor gene, CCR8, is associated With DUSP22 rearrangements in anaplastic large cell lymphoma.
Xing X; Flotte TJ; Law ME; Blahnik AJ; Chng WJ; Huang G; Knudson RA; Ketterling RP; Porcher JC; Ansell SM; Sidhu J; Dogan A; Feldman AL
Appl Immunohistochem Mol Morphol; 2015 Sep; 23(8):580-9. PubMed ID: 25390351
[TBL] [Abstract][Full Text] [Related]
23. Histopathological features and outcomes of DUSP22 rearrangement in primary cutaneous anaplastic large cell lymphoma: a case report and review of the literature.
Nieto-Benito LM; Parra-Blanco V; Gómez-Navarro Y; Menárguez-Palanca J; Pulido-Pérez A
J Eur Acad Dermatol Venereol; 2021 Oct; 35(10):e670-e672. PubMed ID: 34014587
[No Abstract] [Full Text] [Related]
24. Peripheral T-cell lymphomas expressing CD30 and CD15 expand the spectrum of anaplastic large cell lymphoma, ALK-negative.
Ganapathi KA; Nicolae A; Egan C; Geng H; Xi L; Pack SD; McFadden JR; Raffeld M; Jaffe ES; Pittaluga S
Br J Haematol; 2024 May; 204(5):1862-1871. PubMed ID: 38613165
[TBL] [Abstract][Full Text] [Related]
25.
Qiu L; Tang G; Li S; Vega F; Lin P; Wang SA; Wang W; Iyer SP; Malpica L; Miranda RN; Konoplev S; Tang Z; Fang H; Medeiros LJ; Xu J
Haematologica; 2023 Jun; 108(6):1604-1615. PubMed ID: 36453104
[TBL] [Abstract][Full Text] [Related]
26. Primary cutaneous anaplastic large cell lymphoma with DUSP22-IRF4 rearrangement demonstrating a biphasic histopathologic pattern and a complete natural regression.
Kitajima Y; Yamashina M; Hanamoto M; Shijimaya T; Terai S; Nakamaru S; Makimura K; Inoue N; Takeuchi K; Kiyohara T
J Dermatol; 2022 Sep; 49(9):e309-e310. PubMed ID: 35560037
[No Abstract] [Full Text] [Related]
27. IRF4/DUSP22-positive anaplastic large cell lymphoma arising in the setting of chronic olecranon bursitis.
Ku A; Alobeid B
Blood; 2023 Jun; 141(23):2912. PubMed ID: 37289474
[No Abstract] [Full Text] [Related]
28. New developments in non-Hodgkin lymphoid malignancies.
Ganapathi KA; Brown LE; Prakash S; Bhargava P
Pathology; 2021 Apr; 53(3):349-366. PubMed ID: 33685720
[TBL] [Abstract][Full Text] [Related]
29. ALK-positive anaplastic large-cell lymphoma in adults: an individual patient data pooled analysis of 263 patients.
Sibon D; Nguyen DP; Schmitz N; Suzuki R; Feldman AL; Gressin R; Lamant L; Weisenburger DD; Rosenwald A; Nakamura S; Ziepert M; Maurer MJ; Bast M; Armitage JO; Vose JM; Tilly H; Jais JP; Savage KJ
Haematologica; 2019 Dec; 104(12):e562-e565. PubMed ID: 31004022
[No Abstract] [Full Text] [Related]
30. RNAseq identification of FISH-cryptic BCL6::TP63 rearrangement in ALK-negative anaplastic large-cell lymphoma.
Ahmed N; Ketterling RP; Nowakowski GS; Dasari S; Feldman AL
Histopathology; 2022 Aug; 81(2):275-278. PubMed ID: 35586895
[No Abstract] [Full Text] [Related]
31. Safety and effective salvage regimen comprising a novel combination of brentuximab vedotin, L-asparaginase, and dexamethasone for refractory anaplastic large cell lymphoma, anaplastic lymphoma kinase negative.
Kawamoto K; Suzuki T; Kasami T; Kiryu M; Sone H; Miyoshi H; Ohshima K; Takizawa J
Hematol Oncol; 2019 Apr; 37(2):212-214. PubMed ID: 30394560
[No Abstract] [Full Text] [Related]
32. Central nervous system ALK-negative anaplastic large cell lymphoma with IRF4/DUSP22 rearrangement.
Magaki S; Satyadev R; Chen Z; Yung KS; Vinters HV; Kinney MC; Said JW
Brain Tumor Pathol; 2022 Jan; 39(1):25-34. PubMed ID: 34791573
[TBL] [Abstract][Full Text] [Related]
33. Primary effusion anaplastic large cell lymphoma with indolent clinical course and IRF4/DUSP22 rearrangement: a case report expanding the spectrum of effusion-based lymphoma.
Yuan CT; Cheng AL; Hou HA
Virchows Arch; 2023 Mar; 482(3):641-645. PubMed ID: 35984488
[TBL] [Abstract][Full Text] [Related]
34. ALK-positive anaplastic large cell lymphoma with an unusual alveolar growth pattern.
Yu G; Gao Z; Huang X
Int J Clin Exp Pathol; 2014; 7(12):9086-9. PubMed ID: 25674293
[TBL] [Abstract][Full Text] [Related]
35. Phase II trial of dose-adjusted EPOCH in untreated systemic anaplastic large cell lymphoma.
Dunleavy K; Pittaluga S; Shovlin M; Roschewski M; Lai C; Steinberg SM; Jaffe ES; Wilson WH
Haematologica; 2016 Jan; 101(1):e27-9. PubMed ID: 26518748
[No Abstract] [Full Text] [Related]
36. ALK-negative anaplastic large cell lymphoma with
Sibon D; Bisig B; Bonnet C; Poullot E; Bachy E; Cavalieri D; Fataccioli V; Bregnard C; Drieux F; Bruneau J; Lemonnier F; Dupuy A; Bossard C; Parrens M; Bouabdallah K; Ketterer N; Berthod G; Cairoli A; Damaj G; Tournilhac O; Jais JP; Gaulard P; De Leval L
Haematologica; 2023 Jun; 108(6):1590-1603. PubMed ID: 36453105
[TBL] [Abstract][Full Text] [Related]
37. Anaplastic large cell lymphomas with equivocal DUSP22 FISH results: recommendations for clinical reporting and diagnostic evaluation.
Fadl A; Oishi N; Shi M; Dasari S; Ansell SM; Ketterling RP; Feldman AL
Hum Pathol; 2023 Nov; 141():6-14. PubMed ID: 37633531
[TBL] [Abstract][Full Text] [Related]
38. Discovery of recurrent t(6;7)(p25.3;q32.3) translocations in ALK-negative anaplastic large cell lymphomas by massively parallel genomic sequencing.
Feldman AL; Dogan A; Smith DI; Law ME; Ansell SM; Johnson SH; Porcher JC; Ozsan N; Wieben ED; Eckloff BW; Vasmatzis G
Blood; 2011 Jan; 117(3):915-9. PubMed ID: 21030553
[TBL] [Abstract][Full Text] [Related]
39. Expression of p63 protein in anaplastic large cell lymphoma: implications for genetic subtyping.
Wang X; Boddicker RL; Dasari S; Sidhu JS; Kadin ME; Macon WR; Ansell SM; Ketterling RP; Rech KL; Feldman AL
Hum Pathol; 2017 Jun; 64():19-27. PubMed ID: 28153507
[TBL] [Abstract][Full Text] [Related]
40. Cutaneous presentation of enteropathy-associated T-cell lymphoma masquerading as a DUSP22-rearranged CD30+ lymphoproliferation.
Bisig B; Cairoli A; Gaide O; Somja J; Bregnard C; Gaulard P; Xerri L; Lefort K; Missiaglia E; Gilliet M; Hohl D; Guenova E; de Leval L
Virchows Arch; 2022 Oct; 481(4):653-657. PubMed ID: 35366115
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
